DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy.

Background: Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of decitabine (DAC) in the European Union (EU) in 2012 for the treatment of patients with AML ≥65 years marks the potential for hypomethylating agents in elderly AML. Nevertheless the situation is dissatisfactory and the quest for novel treatment approaches, including combination epigenetic therapy is actively ongoing.

Aerobic physical activity among third- to sixth-grade children.

We observed the level of activity, and determined which of 24 third- to sixth-grade children were present during that activity, for two weekdays per child. No events of aerobic activity, as defined by nationally accepted criteria, were detected in that 48 days of observation. By a less stringent criterion, only half the children engaged in aerobic activity on any one day.

Ambulatory blood pressure monitoring in diabetic males: a method for detecting blood pressure elevations undisclosed by conventional methods.

Twenty-one diabetic males, ages 20 to 61 years (mean 48.4 +/- 10.5) and 14 healthy males, 22 to 59 years (mean 42.